Organizing Committee

Nissim Benvenisty, MD, PhD
The Hebrew University of Jerusalem, Israel

Robert Blelloch, MD, PhD
University of California, San Francisco, USA

Daniel Marshak, PhD
Consulting & Advisory, USA

Melissa Carpenter, PhD
ElevateBio, USA

Assem Ziady, PhD
Cincinnati Children’s Hospital Medical Center, USA

John Tisdale, MD
NIH/NHLBI, USA

Shen Shen, PhD
Vertex Pharmaceuticals, USA

Gerhard Bauer, Professor
University of California, School of Medicine, USA

IS Madison 1000x220_2

Call for Abstracts

Abstract submission for the 2022 Madison International Symposium has been extended and will now close at 11:59 PM EST on Tuesday, 12 July 2022!

 

Abstract-selected oral presentations will only be presented in person.

Oral abstract submissions will be considered for a short talk during one of the sessions: 

  • Diabetes & Metabolic Diseases
  • Hematopoietic Diseases
  • In Utero Cell and Gene Therapy
  • Central Nervous System Diseases
  • Muscle Disorders 
  • Cell & Gene Therapy Manufacturing 
  • Visual System
  • Immuno-Oncology: CAR-T and NK cell therapies
  • New Technologies and Future Directions 

Accepted abstracts not chosen for in-person oral presentation will automatically be considered for a poster presentation, which will take place in-person and virtually.

There is a non-refundable $35.00 USD abstract submission fee for each abstract submitted.

Presentation notifications will be sent by the end of July 2022. 

Please contact abstracts@isscr.org with any questions. 


Abstract Submission Requirements

All abstract submissions are screened by the Program Committee to ensure that they meet these standards. Failure to comply with these terms constitutes grounds for abstract rejection.

  • Substantial experimental, calculated, or theoretical results must be included.
  • Clinical case studies will not be considered
  • Abstracts of commercial products must include experimentally derived, quantitative data
  • Abstracts must adhere to the principles in the ISSCR Guidelines for Stem Cell Research and Clinical Translation.
  • Results are the work of the listed author(s).
  • Abstracts must be based on results that have not been previously published in their entirety in any journal nationally or internationally, before submission to this ISSCR event
  • Abstracts must adhere to the Abstract Submission Agreement. 

Abstract Submission Overview

To ensure a smooth submission experience, submitters should review these items carefully and have them in advance to have the correct data on hand. Average submission can take up to 20 minutes.

  • Abstract Title: Abstract Titles are limited to 175 characters, including spaces. Titles should be in ALL CAPS. 
  • Submission Type: Select oral or poster presentation type.
  • Presenter: The head author should be listed as the presenting author for the abstract. Each abstract may indicate only one presenting author.
  • Co-author(s): Each abstract can include a maximum of 24 co-authors.
    • When adding co-authors for this submission be certain department and institution names are entered identically for all authors who share them on this abstract.
    • Review your entries for correct spelling and capitalization (capitalize only the first letter of each name) to ensure your author block is printed correctly in meeting materials.
  • Abstract Text: Abstracts are limited to 2,000 letters, not including spaces. Abstracts must be formatted as one paragraph; those not in compliance will be edited to conform to this format. Abstract text should not include section titles (such as Methods, Results, Conclusions), tables, graphs, charts, diagrams, authors, or references or acknowledge funding sources. 
  • Session Topics: Choose the most appropriate session topic that fits your research. Topics will be used for poster hall organization. The topics are:
    • Diabetes & Metabolic Diseases
    • Hematopoietic Diseases
    • In Utero Cell and Gene Therapy
    • Central Nervous System Diseases
    • Muscle Disorders 
    • Cell & Gene Therapy Manufacturing 
    • Visual System
    • Immuno-Oncology: CAR-T and NK cell therapies
    • New Technologies and Future Directions 
  • Keywords: Indicate three keywords that highlight the main topics of your abstract. 
  • Funding Source: You may choose to include funding sources or grants that your work. This field is limited to 500 characters, not including spaces.
  • Experimental treatments to human subjectsYou must indicate if the research described involves experimental stem cell-based treatments to human subjects, and if so, share the institutional review board and/or national or local regulatory agency that reviewed it, the clinical trial reference numbers and other identifying information (i.e. name of the granting authority, and URL, etc.)

Submission Fee

There is a non-refundable $35.00 USD abstract submission fee for each abstract submitted. Payment must be made by credit card (MasterCard, Visa, American Express and Discover accepted).


Review & Notification of Result

Submitted abstracts will be reviewed by the committee. Acceptance/rejection of abstracts will be notified to the submitters via email. Presentation notifications will be sent by Thursday, 29 July 2022.